Navigo Proteins

2:45 PM - 3:00 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104B
Navigo Proteins is a fast-growing German biotech developing next-generation targeted therapeutics, based on novel, proprietary target binding proteins called Affilin®. Our Precision Targeting Toolbox offers customized mono, bi-/ or multi-specific Affilin® which can be coupled to various functional moieties like cytotoxic payloads and radioactive isotopes. Together with our proprietary half-life optimizing modules called HEAD®, we create Afflin®-based therapies, with superior targeting and an optimized in vivo distribution.
With a focus in precision oncology and a drive to bring innovative, best-in-class therapies to patients, the Navigo team is designing novel Affilin® against Tumor Associated Antigens (TAAs) as well as immuno-oncology (I/O) targets. With a growing portfolio of ‘Off-the shelf’ Affilin® directly available for partnering, and promising pre-clinical data, Navigo is looking for strategic partnerships to (co-) develop and commercialize Affilin®-based biopharmaceuticals.
Not Provided
Not Provided
Company Type:
Not Provided
Company HQ State:
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
HER2-Affilin® Radioligand therapy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Sr, Manager Business Development
Navigo Proteins